"Today's approval provides an additional treatment option for patients with cUTIs who have limited or no alternative treatment options," said John Farley, M.D., M.P.H., acting director of the Office of Infectious Diseases in the FDA's Center for Drug Evaluation and Research. "A key global challenge the FDA faces as a public health agency is addressing the threat of antimicrobial-resistant infections, like cUTIs. This approval represents another step forward in the FDA's overall efforts to ensure safe and effective antimicrobial drugs are available to patients for treating infections."
The safety and effectiveness of Fetroja was demonstrated in a study of 448 patients with cUTIs. Of the patients who were administered Fetroja, 72.6% had resolution of symptoms and eradication of the bacteria approximately seven days after completing treatment, compared with 54.6% in patients who received an alternative antibiotic. The clinical response rates were similar between the two treatment groups.
More on Marylandian
- Evolve IP Completes Flex Certification for WebEx Calling and Meetings Solutions
- Trans Actor Jesse Todd Tapped for Lead Role in Upcoming Film "Pink Moon"
- Zbones Discovers Additional Eardrums In Humans!
- Aldo Dinelli, Houston's Top Celebrity Jeweler - Talks Diamonds
- Waveband Communications Introduces Accessories for the Motorola XPR7550
Labeling for Fetroja includes a warning regarding the higher all-cause mortality rate observed in Fetroja-treated patients compared to those treated with other antibiotics in a trial in critically ill patients with multidrug-resistant Gram-negative bacterial infections. The cause of the increase in mortality has not been established. Some of the deaths were a result of worsening or complications of infection, or underlying co-morbidities. The higher all-cause mortality rate was observed in patients treated for hospital-acquired/ventilator-associated pneumonia (i.e.nosocomial pneumonia), bloodstream infections, or sepsis. The safety and efficacy of Fetroja has not been established for the treatment of these types of infections.
The most common adverse reactions observed in patients treated with Fetroja included diarrhea, constipation, nausea, vomiting, elevations in liver tests, rash, infusion site reactions, candidiasis (yeast infection), cough, headache and hypokalemia (low potassium). Fetroja should not be used in individuals with a known history of severe hypersensitivity to beta-lactam antibacterial drugs.
Fetroja received the FDA's Qualified Infectious Disease Product (QIDP) designation. The QIDP designation is given to antibacterial and antifungal drug products intended to treat serious or life-threatening infections under the Generating Antibiotic Incentives Now (GAIN) title of the FDA Safety and Innovation Act. As part of QIDP designation, Fetroja was granted Priority Review under which the FDA's goal is to take action on an application within an expedited time frame.
More on Marylandian
- Santia Deck Makes History; Signs Record Breaking Deal With Highly-Anticipated WFLA
- Dbvisit Announces Release of Dbvisit Standby Snapshot
- Apollo Brands® Announces Exclusive Distribution Agreement Bringing Apollo Energy Gum® and Golf Gum® to The Nordic Countries
- Sandline Discovery Leverages NexLP's Cognitive AI to Deliver Leading Behavioral and Linguistic Intelligence
- Streetsense Receives 3 National Tourism Awards for 'Begin at Bothell' Website
The FDA granted the approval of Fetroja to Shionogi & Co., Ltd.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Media Inquiries: Kristen Pluchino, 240-402-0861, Kristen.Pluchino@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
SOURCE U.S. Food and Drug Administration
Filed Under: Business
Latest on Marylandian
- Kirk Stange And Stange Law Firm, PC Proud To Support Kids Rock Cancer On Their 10th Year Anniversary
- Ottawa-based Business to Create Car Accident Reduction Technology
- CEO Coaching International Congratulates Client Synlio on Sale to Boston-Based Building Engines
- Sprawling New Novel, WE OF THE FORSAKEN WORLD, Tackles Themes of Global Connection
- QuiAri Promotes Brad Stewart To Director Of Field Development
- Maryland Wine and Grape Promotion Fund Accepting Grant Applications
- Pilot Trading Expands Its Suite of Broker Integrations by going Live with TradeStation
- Right Cars Vehicle Rental announce the appointment of Alison Lee as Customer Service Director
- NFL Great Shawne Merriman To Host The 17th Annual "Lights On" Coat Drive to Benefit Veterans
- The Azores - the world's first certified archipelago
- CopyLady Earns ENX Magazine Elite Dealer of the Year Award
- Auto Driveaway acquires a majority interest in Sparkle Mobile LLC
- Freedom Spreads in South America
- SANS Announces Agenda for San Diego 2020 Cyber Security Training Event
- Maryland: State to Cover 2020 Premiums for Farmers Participating in Federal Dairy Margin Coverage Program
- Symplast Founder Dr. Kusuma to Present Telehealth Session at the 2019 Florida Plastic Surgery Forum
- FileFlex Enterprise lets SharePoint users easily and securely share files with non-SharePoint users
- As a Black Man, What Happens in Vegas (at Circus Circus) Stays with Me Forever
- Maryland Department of Agriculture's Annual Tree Lighting Ceremony Encourages Residents to Buy Locally-Grown Holiday Trees
- Grammy Nominated Bokanté Brings World Music to the Weinberg Center